GPS Wealth Strategies Group LLC Purchases 65 Shares of Insulet Co. (NASDAQ:PODD)

GPS Wealth Strategies Group LLC grew its stake in Insulet Co. (NASDAQ:PODD) by 19.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 405 shares of the medical instruments supplier’s stock after acquiring an additional 65 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Insulet were worth $106,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Algert Global LLC boosted its stake in Insulet by 25.6% in the 2nd quarter. Algert Global LLC now owns 2,254 shares of the medical instruments supplier’s stock worth $455,000 after purchasing an additional 460 shares in the last quarter. Creative Planning grew its position in shares of Insulet by 35.0% in the second quarter. Creative Planning now owns 7,430 shares of the medical instruments supplier’s stock valued at $1,499,000 after purchasing an additional 1,928 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Insulet by 10.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock valued at $202,000 after acquiring an additional 95 shares during the last quarter. Sanctuary Advisors LLC purchased a new position in Insulet in the 2nd quarter valued at $830,000. Finally, Czech National Bank boosted its position in Insulet by 7.0% during the third quarter. Czech National Bank now owns 14,283 shares of the medical instruments supplier’s stock worth $3,324,000 after acquiring an additional 937 shares during the last quarter.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on PODD shares. Barclays lifted their price target on Insulet from $220.00 to $234.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. increased their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Canaccord Genuity Group increased their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Citigroup boosted their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Trading Up 0.2 %

Shares of PODD stock opened at $278.90 on Tuesday. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The business’s 50 day moving average is $268.94 and its two-hundred day moving average is $239.09. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $286.39. The company has a market capitalization of $19.56 billion, a P/E ratio of 47.76, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.13. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the previous year, the company earned $0.71 EPS. Equities analysts forecast that Insulet Co. will post 3.22 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.